The Histologic Diversity of Chromophobe Renal Cell Carcinoma With Emphasis on Challenges Encountered in Daily Practice.
Journal
Advances in anatomic pathology
ISSN: 1533-4031
Titre abrégé: Adv Anat Pathol
Pays: United States
ID NLM: 9435676
Informations de publication
Date de publication:
01 Jul 2022
01 Jul 2022
Historique:
pubmed:
27
4
2022
medline:
10
6
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
Chromophobe renal cell carcinoma (ChRCC) is the third most common renal cell carcinoma in adults. The aim of this review is to provide a comprehensive overview highlighting the broad morphologic spectrum of ChRCC, and offer a practical approach for handling cases in daily practice. For the purpose of this review, we classify ChRCC subtypes as (1) classic, (2) eosinophilic, (3) sarcomatoid, and (4) other rare patterns. The concept of eosinophilic ChRCC has significantly evolved, yet it still is one of the major diagnostic challenges pathologists face in routine practice due to its morphologic overlap with renal oncocytoma. Rare patterns of ChRCC have been described over the last few decades, showing a wide histologic spectrum including those with adenomatoid microcystic pigmented, multicystic, neuroendocrine, small cell, and papillary features. ChRCC represents a heterogenous group of neoplasms, demonstrating varied but unique morphologic and genetic profiles. Although the field of ChRCC knowledge is still evolving, rare patterns can present diagnostic challenges if they are not known to pathologists and/or clinicians. Proper and generous tumor sampling along with careful histologic examination allow for recognition of these rare morphologies. The role of routine molecular testing appears to be limited. From a clinical management standpoint, the rare patterns of ChRCC seem to have no definite clinical implications at present and likely can be managed similarly to usual ChRCC. Finally, we will discuss distinctive novel/emerging renal neoplasms previously considered under the spectrum of ChRCC, low-grade oncocytic renal tumor and eosinophilic vacuolated tumor, with regard to their current significance and implications for future classification strategies.
Identifiants
pubmed: 35470289
doi: 10.1097/PAP.0000000000000349
pii: 00125480-202207000-00002
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
194-207Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
MacLennan GT, Cheng L. Five decades of urologic pathology: the accelerating expansion of knowledge in renal cell neoplasia. Hum Pathol. 2020;95:24–45.
Bannasch P, Schacht U, Storch E. [Morphogenesis and micromorphology of epithelial tumors of the kidney of nitrosomorpholine intoxicated rats. I. Induction and histology (author’s transl)]. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1974;81:311–331.
Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48:207–217.
Thoenes W, Storkel S, Rumpelt HJ, et al. Chromophobe cell renal carcinoma and its variants—a report on 32 cases. J Pathol. 1988;155:277–287.
Storkel S, Steart PV, Drenckhahn D, et al. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:237–245.
Davis CF, Ricketts CJ, Wang M, et al. The Cancer Genome Atlas Research Network. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell. 2014;26:319–330.
Iqbal MA, Akhtar M, Ali MA. Cytogenetic findings in renal cell carcinoma. Hum Pathol. 1996;27:949–954.
Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 1992;4:267–268.
Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356–364.
Crotty TB, Farrow GM, Lieber MM. Chromophobe cell renal carcinoma: clinicopathological features of 50 cases. J Urol. 1995;154:964–967.
Akhtar M, Tulbah A, Kardar AH, et al. Sarcomatoid renal cell carcinoma: the chromophobe connection. Am J Surg Pathol. 1997;21:1188–1195.
Joubert M, Cassagnau E, Boullanger P, et al. Sarcomatoid variant of chromophobe renal cell carcinoma. Report of 2 cases. Ann Pathol. 1997;17:392–395.
Hes O, Michal M, Kinkor Z, et al. Sarcomatous chromophobe cell renal carcinoma. 2 case reports. Cesk Patol. 1999;35:15–19.
Hirokawa M, Shimizu M, Sakurai T, et al. Sarcomatoid renal cell carcinoma with chromophobe cell foci. Report of a case. APMIS. 1998;106:993–996.
Michal M, Hes O, Svec A, et al. Pigmented microcystic chromophobe cell carcinoma: a unique variant of renal cell carcinoma. Ann Diagn Pathol. 1998;2:149–153.
Trpkov K, Williamson SR, Gill AJ, et al. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34:1167–1184.
Alaghehbandan R, Przybycin CG, Verkarre V, et al. Chromophobe renal cell carcinoma: novel molecular insights and clinicopathologic updates. Asian J Urol. 2022;9:1–11.
Hu Y, Hartmann A, Stoehr C, et al. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. J Clin Pathol. 2012;65:254–256.
Miettinen M, McCue PA, Sarlomo-Rikala M, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38:13–22.
Alaghehbandan R, Trpkov K, Tretiakova M, et al. Comprehensive review of numerical chromosomal aberrations in chromophobe renal cell carcinoma including its variant morphologies. Adv Anat Pathol. 2021;28:8–20.
Paner G, Amin M, Moch H, et al. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Chromophobe renal cell carcinoma. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016:27–28.
Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008;32:1822–1834.
Zini L, Leroy X, Lemaitre L, et al. Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants. Eur J Surg Oncol. 2008;34:687–691.
Williamson SR, Gadde R, Trpkov K, et al. Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists. Hum Pathol. 2017;63:149–156.
Akgul M, Williamson SR. Immunohistochemistry for the diagnosis of renal epithelial neoplasms. Semin Diagn Pathol. 2022;39:1–16.
Hes O, Moch H, Reuter VE Moch H, Humphrey PA, Ulbright TM, Reuter VE. Oncocytoma. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016:43–44.
Agaimy A, Hartmann A, Trpkov K, et al. Undifferentiated and dedifferentiated urological carcinomas: lessons learned from the recent developments. Semin Diagn Pathol. 2021;38:152–162.
Ged Y, Chen YB, Knezevic A, et al. Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer. 2019;17:e678–e688.
Cheville JC, Lohse CM, Zincke H, et al. Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol. 2004;28:435–441.
Volpe A, Novara G, Antonelli A, et al. Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int. 2012;110:76–83.
de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25:275–284.
Przybycin CG, Cronin AM, Darvishian F, et al. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011;35:962–970.
Petersson F, Michal M, Franco M, et al. Chromophobe renal cell carcinoma with liposarcomatous dedifferentiation—report of a unique case. Int J Clin Exp Pathol. 2010;3:534–540.
Peckova K, Martinek P, Ohe C, et al. Chromophobe renal cell carcinoma with neuroendocrine and neuroendocrine-like features. Morphologic, immunohistochemical, ultrastructural, and array comparative genomic hybridization analysis of 18 cases and review of the literature. Ann Diagn Pathol. 2015;19:261–268.
Hes O, Vanecek T, Perez-Montiel DM, et al. Chromophobe renal cell carcinoma with microcystic and adenomatous arrangement and pigmentation—a diagnostic pitfall. Morphological, immunohistochemical, ultrastructural and molecular genetic report of 20 cases. Virchows Arch. 2005;446:383–393.
Dundr P, Pesl M, Povysil C, et al. Pigmented microcystic chromophobe renal cell carcinoma. Pathol Res Pract. 2007;203:593–597.
Kuroda N, Tamura M, Hes O, et al. Chromophobe renal cell carcinoma with neuroendocrine differentiation and sarcomatoid change. Pathol Int. 2011;61:552–554.
Parada DD, Pena KB. Chromophobe renal cell carcinoma with neuroendocrine differentiation. APMIS. 2008;116:859–865.
Michalova K, Tretiakova M, Pivovarcikova K, et al. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: a study of 8 cases with papillary architecture. Ann Diagn Pathol. 2019;44:151448.
Gutierrez FJQ, Panizo A, Tienza A, et al. Cytogenetic and immunohistochemical study of 42 pigmented microcystic chromophobe renal cell carcinoma (PMChRCC). Virchows Arch. 2018;473:209–217.
Zhao M, Wang YB, Zhang Q, et al. Pigmented microcystic chromophobe renal cell carcinoma: a clinicopathologic analysis of five cases. Zhonghua Bing Li Xue Za Zhi. 2018;47:926–930.
Zhai QJ, Black J, Ayala AG, et al. Histologic variants of infiltrating urothelial carcinoma. Arch Pathol Lab Med. 2007;131:1244–1256.
Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome. Am J Surg Pathol. 2016;40:865–875.
Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol. 2014;38:627–637.
Foix MP, Dunatov A, Martinek P, et al. Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant. Virchows Arch. 2016;469:669–678.
Skenderi F, Ulamec M, Vranic S, et al. Cystic renal oncocytoma and tubulocystic renal cell carcinoma: morphologic and immunohistochemical comparative study. Appl Immunohistochem Mol Morphol. 2016;24:112–119.
Trpkov K, Yilmaz A, Uzer D, et al. Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology. 2010;57:893–906.
MacLennan GT, Bostwick DG. Tubulocystic carcinoma, mucinous tubular and spindle cell carcinoma, and other recently described rare renal tumors. Clin Lab Med. 2005;25:393–416.
Tran T, Jones CL, Williamson SR, et al. Tubulocystic renal cell carcinoma is an entity that is immunohistochemically and genetically distinct from papillary renal cell carcinoma. Histopathology. 2016;68:850–857.
Tretiakova M, Mehta V, Kocherginsky M, et al. Predominantly cystic clear cell renal cell carcinoma and multilocular cystic renal neoplasm of low malignant potential form a low-grade spectrum. Virchows Arch. 2018;473:85–93.
Montironi R, Cheng L, Lopez-Beltran A, et al. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Multilocular cystic renal neoplasm of low malignant potential. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016:22.
Michal M, Amin MB, Delahunt B, et al. Moch H, Humphrey PA, Ulbright TM, Reuter VE. Mixed epithelial and stromal tumour family. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Lyon, France: International Agency for Research on Cancer; 2016:70–71.
Guy L, Begin LR, Oligny LL, et al. Searching for an intrinsic neuroendocrine cell in the kidney. An immunohistochemical study of the fetal, infantile and adult kidney. Pathol Res Pract. 1999;195:25–30.
Mokhtar GA, Al-Zahrani R. Chromophobe renal cell carcinoma of the kidney with neuroendocrine differentiation: a case report with review of literature. Urol Ann. 2015;7:383–386.
Ohe C, Kuroda N, Matsuura K, et al. Chromophobe renal cell carcinoma with neuroendocrine differentiation/morphology: a clinicopathological and genetic study of three cases. Hum Pathol Case Rep. 2014;1:31–39.
Rogala J, Kojima F, Alaghehbandan R, et al. Small cell variant of chromophobe renal cell carcinoma: clinicopathologic, and molecular-genetic analysis of 10 cases. Bosn J Basic Med Sci. 2022. doi: 10.17305/bjbms.2021.6935. [Epub ahead of print].
doi: 10.17305/bjbms.2021.6935
Shimazaki H, Tanaka K, Aida S, et al. Renal oncocytoma with intracytoplasmic lumina: a case report with ultrastructural findings of “oncoblasts”. Ultrastruct Pathol. 2001;25:153–158.
Hes O, Michal M, Boudova L, et al. Small cell variant of renal oncocytoma—a rare and misleading type of benign renal tumor. Int J Surg Pathol. 2001;9:215–222.
Eble JN, Hull MT. Morphologic features of renal oncocytoma: a light and electron microscopic study. Hum Pathol. 1984;15:1054–1061.
Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumour of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75:174–184.
Lerma LA, Schade GR, Tretiakova MS. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex. Hum Pathol. 2021;116:1–11.
Kravtsov OGS, Cheville J, Hererra Hernandez L, et al. Low grade oncocytic tumor of kidney (CK7-positive, CD117-negative). A single institution experience with incidence and clinicopathologic characteristics. Mod Pathol. 2020;114:9–18.
Guo Q, Liu N, Wang F, et al. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China. Virchows Arch. 2021;478:449–458.
Akgul M, Al-Obaidy KI, Cheng L, et al. Low-grade oncocytic tumour expands the spectrum of renal oncocytic tumours and deserves separate classification: a review of 23 cases from a single tertiary institute. J Clin Pathol. 2021. [Epub ahead of print].
Kapur P, Gao M, Zhong H, et al. Germline and sporadic mTOR pathway mutations in low-grade oncocytic tumor of the kidney. Mod Pathol. 2022;35:333–343.
Ishikawa N, Kimura N, Yoshida T, et al. A case of low-grade oncocytic tumor/chromophobe renal cell carcinoma (oncocytic variant) of the kidney. Case Rep Pathol. 2021;2021:6684777.
Sharma D, Pai T, Prakash G, et al. Low-grade oncocytic tumor: report of two cases of an emerging entity in the spectrum of oncocytic renal neoplasms. Turk Patoloji Derg. 2021. [Epub ahead of print].
Morini A, Drossart T, Timsit MO, et al. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1. Mod Pathol. 2022;35:352–360.
Skala SL, Wang X, Zhang Y, et al. Next-generation RNA sequencing-based biomarker characterization of chromophobe renal cell carcinoma and related oncocytic neoplasms. Eur Urol. 2020;78:63–74.
Tong K, Hu Z. FOXI1 expression in chromophobe renal cell carcinoma and renal oncocytoma: a study of The Cancer Genome Atlas transcriptome-based outlier mining and immunohistochemistry. Virchows Arch. 2021;478:647–658.
He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018;473:725–738.
Chen YB, Mirsadraei L, Jayakumaran G, et al. Somatic mutations of TSC2 or MTOR characterize a morphologically distinct subset of sporadic renal cell carcinoma with eosinophilic and vacuolated cytoplasm. Am J Surg Pathol. 2019;43:121–131.
Trpkov K, Bonert M, Gao Y, et al. High-grade oncocytic tumour (HOT) of kidney in a patient with tuberous sclerosis complex. Histopathology. 2019;75:440–442.
Kapur P, Gao M, Zhong H, et al. Eosinophilic vacuolated tumor of the kidney: a review of evolving concepts in this novel subtype with additional insights from a case with MTOR mutation and concomitant chromosome 1 loss. Adv Anat Pathol. 2021;28:251–257.
Gupta S, Jimenez RE, Herrera-Hernandez L, et al. Renal neoplasia in tuberous sclerosis: a study of 41 patients. Mayo Clin Proc. 2021;96:1470–1489.
Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021;34:1392–1424.
Delahunt B, Cheville JC, Martignoni G, et al. Members of the IRTP. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490–1504.
Delahunt B, McKenney JK, Lohse CM, et al. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis. Am J Surg Pathol. 2013;37:311–322.
Avulova S, Cheville JC, Lohse CM, et al. Reply to Riuko Ohashi, Arndt Hartmann, Holger Moch, and Guido Martignoni’s Letter to the Editor re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading of chromophobe renal cell carcinoma: evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur Urol 2021;79:225–231: two-, Three-, or four-tiered grading of chromophobe renal cancer: that’s the question!. Eur Urol. 2021;80:e19.
Ohashi R, Hartmann A, Martignoni G, et al. Re: Svetlana Avulova, John C. Cheville, Christine M. Lohse, et al. Grading chromophobe renal cell carcinoma: evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur Urol 2021;79:225–231: two-, three-, or four-tiered grading of chromophobe renal cancer: that’s the question! Eur Urol. 2021;80:e17–e18.
Avulova S, Cheville JC, Lohse CM, et al. Grading chromophobe renal cell carcinoma: evidence for a four-tiered classification incorporating coagulative tumor necrosis. Eur Urol. 2021;79:225–231.
Ohashi R, Martignoni G, Hartmann A, et al. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch. 2020;476:409–418.
Garje R, Elhag D, Yasin HA, et al. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160:103287.